Contents

#### **Preface XI**


Preface

most important from a patient's perspective.

searchers, as well as many others.

Multiple myeloma is the second most common haematological malignancy. This book does not provide a comprehensive overview of the disease but offers a collection of chapters with in-depth information on distinct hot topics in the diagnostic, research and therapeutic fields. On the biological side, the authors show plasticity of myeloma cells and describe the innova‐ tive models to assess multiple myeloma biology. On the clinical side, the authors analyse current therapeutic development. Pharmacotherapy of multiple myeloma is an example of the fast introduction of scientific discoveries into clinics. The dynamics of testing new drugs for multiple myeloma treatment in clinical trials is breathtaking. Scientific discoveries have uncovered complicated pathogenesis of multiple myeloma; complicated reactions to treat‐ ment lead to creation of super cocktails. This strategy is most beneficial for the patient, but it is not yet personalized medicine. The curability of multiple myeloma is a question that is being discussed by the entire professional myeloma world. Regardless of your position in this debate, some professionals are missing the vital point in this debate - the incredible im‐ provement in treatment options. Consequently, improvement of prognosis is a fact which is

This book will be of interest to medical professionals specializing in hematooncology, re‐

**Prof. Roman Hajek**

Czech Republic

Department of Pathological Physiology, Faculty of Medicine, Masaryk University,

